Safety and Efficacy of Oral Brivaracetam versus Levetiracetam as Monotherapy in Children Aged 1 Month to 14 Years with Newly Diagnosed Epilepsy
Year: 2025
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Background: Epilepsy is one of the most common chronic neurological disorders in childhood. Objective: To compare the safety and efficacy of oral brivaracetam, and levetiracetam as monotherapy in children with newly diagnosed epilepsy. Methods: This randomized controlled trial was conducted at the Pediatric Neurology Department, Children Hospital Multan, Pakistan, during August 2024–February 2025. A total of 102 children aged 1 month to 14 years with newly diagnosed epilepsy, were randomized to receive oral brivaracetam or levetiracetam monotherapy. Seizure freedom at 3-month, seizure frequency reduction, time to 1st breakthrough seizure, and adverse effects were documented. Data analysis was performed using IBM-SPSS Statistics, version 26.0, taking p<0.05 as significant. Results: Among 102 enrolled children, the median age was 6.3 (IQR 3.5-10.2) years, while 55 (55.9%) were males. At 3-month, 97 (95.1%) children completed follow-up, while seizure freedom was achieved in 39 (79.6%) brivaracetam-treated, and 35 (72.9%) levetiracetam-treated children (p=0.332). The median reduction in monthly seizure days was 4.5 (IQR 3.2–6.0) with brivaracetam, and 4.2 (IQR 3.0–6.0) with levetiracetam (p=0.474). The median time to 1st breakthrough seizure was 35.6 (IQR 20.2–60.4) days with brivaracetam, and 30.3 (IQR 18.0–55.5) days with levetiracetam (p=0.563). Adverse events occurred in 44 (45.4%) children, mainly somnolence (11.3%) and irritability (10.3%), without any significant differences (p>0.05) Conclusion: Brivaracetam, and levetiracetam demonstrated comparable efficacy in achieving seizure freedom and reducing seizure frequency in children with newly diagnosed epilepsy.
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: brivaracetam, levetiracetam, newly diagnosed epilepsy, pediatric epilepsy, antiepileptic drug monotherapy, seizure freedom, seizure frequency reduction, breakthrough seizures, adverse drug reactions, sleepiness, drug efficacy comparison, drug safety in children, antiepileptic drugs, Pakistan, Multan, Pakistan, Multan
Open Access status: bronze
OpenAlex ID: W7220552998
